Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies

Nicolas Penel, Loïc Lebellec, Jean-Yves Blay, Yves-Marie Robin,

Crit Rev Oncol Hematol

https://doi.org/10.1016/j.critrevonc.2020.102960

Abstract

We summarize herein the literature data about molecular targeted therapies in sarcomas and conjunctive tissue intermediate malignancies. For each clinical setting, the level of evidence, the mechanism of action and the target are described. The two major axes include (i) identification of subgroups of tumors with druggable alteration irrespective of the histological diagnosis (e.g. NTRK), and (ii) druggable target of pathway related to the physiopathology of the tumor: denosumab and bone giant cell tumor, imatinib and soft tissue giant cell tumor, mTOR inhibitor and PECOMA.